Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites. Educating physicians on a fully global scale since 2005! We make positive changes to clinical practice, with the ultimate objective of improving patient and community health. Working alongside leading medical experts, societies and industry, our mission is to provide practical, expert opinions to support best practices for busy Healthcare Professionals globally, by translating published data into easily digestible and timely updates Home of: - touchONCOLOGY - touchENDOCRINOLOGY - touchOPHTHALMOLOGY - touchNEUROLOGY - touchCARDIOLOGY - touchINFECTIOUSDISEASES - touchIMMUNOLOGY - touchRESPIRATORY - touchHAEMATOLOGY - touchDERMATOLOGY This information is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations.
Episodes
Wednesday Jul 20, 2022
Wednesday Jul 20, 2022
touchCONGRESS for touchONCOLOGY
Listen to Professor Giuseppe Saglio (Italy) cover key data presented at the EHA Hybrid Conference 2022 on the efficacy and safety of current and emerging treatments for CML, and how these may influence clinical practice, as well as expert insights and interpretation from Professor François-Xavier Mahon (France) and Professor Dietger Niederwieser (Germany).
Overview
- Data review with Professor Giuseppe Saglio (00:54)
- Expert interview with Professor Giuseppe Saglio, Professor François-Xavier Mahon and Professor Dietger Niederwieser (32:50)
Interview questions
- When considering the new 96-week data for asciminib from the ASCEMBL trial, how do you think these results will impact clinical practice? (35:00)
- In patients with absence of an optimal response on therapy, what can we learn from new data on switching TKIs? (41:00)
- What have we learnt about the clinical considerations for TKI discontinuation?(47:09)
- Extended use of TKIs is now commonplace; what safety aspects have we seen from long-term follow-up studies?(52:26)
- How should dose modifications be used for TKIs in clinical practice? (57:39)
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical educational grant from Novartis Pharmaceuticals. This activity is provided by touchIME.
For further information visit our website: www.touchoncology.com
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.